The U.S. Food and Drug Administration has upgraded the recall of Vitruvias Therapeutics’ 30mg thyroid tablets to a Class I designation.
This is the agency’s highest-risk category and indicates that the medication may cause severe health consequences or even death.
The voluntary recall, initiated last month, covers one lot of Thyroid Tablets, USP, identified by lot number 504950 and National Drug Code 69680-166-00.
The tablets have an expiration date of September 30, 2026, and were distributed nationwide between January 31 and September 30, 2025. Around 1,955 of the 3,655 units were sold.
Further testing confirmed the tablets could be superpotent, meaning they are stronger than intended.
,According to the FDA, taking superpotent thyroid medicine can cause an overactive thyroid, leading to symptoms such as weight loss, heat intolerance, fatigue, high blood pressure, chest pain, rapid heartbeat and heart rhythm problems.
Elderly patients, pregnant women and infants are at the highest risk, especially with prolonged use.
Class I recalls indicate a reasonable probability that exposure to the product could cause serious adverse health effects or death.
Vitruvias Therapeutics said it had received no reports of adverse events linked to the lot as of the recall notice’s August 24 publication.
The company recently said it has ceased operations, and its products are now owned or distributed by H2-Pharma LLC.
The post US Links Famous Thyroid Medicine to Severe Health Issues appeared first on ProPakistani.
